What is DA Davidson’s Forecast for PBH FY2025 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at DA Davidson lifted their FY2025 earnings per share estimates for Prestige Consumer Healthcare in a report released on Monday, February 10th. DA Davidson analyst L. Weiser now anticipates that the company will earn $4.50 per share for the year, up from their prior estimate of $4.46. DA Davidson has a “Buy” rating and a $104.00 price target on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s Q4 2025 earnings at $1.30 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%.

Other analysts have also recently issued research reports about the company. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Finally, Canaccord Genuity Group upped their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Trading Down 2.1 %

Shares of PBH opened at $84.18 on Tuesday. The stock has a 50-day moving average price of $79.30 and a 200 day moving average price of $75.74. Prestige Consumer Healthcare has a one year low of $62.35 and a one year high of $88.36. The company has a market capitalization of $4.16 billion, a P/E ratio of 19.71, a P/E/G ratio of 2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.10 and a current ratio of 3.68.

Insider Transactions at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in PBH. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after purchasing an additional 152 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares in the last quarter. Headlands Technologies LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $40,000. Finally, nVerses Capital LLC grew its holdings in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after buying an additional 400 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.